Werewolf Therapeutics, Inc. — Form 8-K Summary
Reporting date: April 12, 2022; filed April 15, 2022. This current report discloses a material financing agreement and a board resignation. It does not report quarterly or annual operating results.
Business Context and Key Financial Terms
- Werewolf entered into an amended and restated Loan and Security Agreement with Pacific Western Bank, replacing the prior May 2020 agreement and subsequent amendments.
- The facility provides for up to $40.0 million of term loans: an initial tranche of up to $20.0 million and a second tranche of up to $20.0 million subject to the FDA accepting two investigational new drug applications by March 31, 2023.
- The term loans were undrawn as of April 12, 2022; therefore, the filing does not report new debt outstanding, financing proceeds, revenue, profit, cash flow, or margins.
- Interest accrues at the greater of the applicable prime rate plus 0.5% or 4.50%, with monthly interest payments.
- Interest-only payments are due until the amortization date, generally February 28, 2024, extendable to August 31, 2024 if specified conditions are met. Principal is then payable over 24 monthly installments.
- All outstanding principal and interest is due February 28, 2026, extendable to August 31, 2026 upon satisfaction of specified conditions.
Material Changes and Financing Obligations
- The amended agreement permits prepayment without premium or penalty.
- Werewolf must raise at least $50.0 million in aggregate gross cash proceeds by September 30, 2023 through equity issuance, strategic partnerships, or a similar transaction.
- After receiving those proceeds, the company must maintain at least $20.0 million of unrestricted cash in accounts with Pacific Western Bank.
- Obligations are secured by the company’s personal property, excluding intellectual property, and may be accelerated upon an event of default.
- The agreement includes restrictions on additional debt and liens, mergers, dividends, asset transfers, and certain investments, subject to specified exceptions.
- A success fee may be payable upon certain corporate transactions: generally the greater of $200,000 or 2% of drawn amounts for transactions on or before March 31, 2023, and thereafter the greater of $400,000 or 4% of drawn amounts. The obligation can survive for ten years after repayment of the loans.
Management, Outlook, and Risks
- The facility provides potential liquidity but was not funded at the closing date; actual availability and future borrowing remain subject to the agreement’s conditions.
- Failure to meet the required capital raise, minimum cash balance, or other covenants could constitute an event of default. Pacific Western Bank may also act upon certain material adverse effects.
- The company faces floating-rate exposure on any amounts drawn and potential repayment obligations beginning on the amortization date.
- On April 12, 2022, Sakae Asanuma resigned from the board, effective April 15, 2022. The filing does not provide a reason for the resignation.
Investor Verification Points
- Verify whether any portion of the $40.0 million facility was subsequently drawn and the resulting debt balance.
- Verify the company’s ability to satisfy the $50.0 million capital-raising requirement and the $20.0 million minimum unrestricted cash requirement.
- Review the complete Loan and Security Agreement for borrowing conditions, covenant exceptions, default provisions, and the success-fee calculation.
- Assess future interest expense and repayment needs under applicable prime-rate changes.
- Review subsequent filings for board composition changes, financing transactions, FDA submissions, and any covenant waivers or defaults.